Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 4, 2005 - Issue 3
Submit an article Journal homepage
102
Views
14
CrossRef citations to date
0
Altmetric
Review

Safety of lopinavir/ritonavir for the treatment of HIV-infection

Martin VogelUniversity of Bonn Department of Internal Medicine I, BonnGermanyTel: +49 228 287 6558; Fax: +49 228 287 5034;E-mail: [email protected]
&
Jürgen K RockstrohUniversity of Bonn Department of Internal Medicine I, BonnGermanyTel: +49 228 287 6558; Fax: +49 228 287 5034;E-mail: [email protected]
Pages 403-420 | Published online: 10 May 2005

Bibliography

  • LEE LM, KARON JM, SELIK R, NEAL JJ, FLEMING PL: Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. /AMA (2001) 285:1308–1315.
  • MOCROFT A, LEDERGERBER B, KATLAMA C et al: Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 362:22–29.
  • SMITH KY: Selected metabolic and morphologic complications associated with highly active antiretroviral therapy. J. Infect. Dis. (2002) 185:S123–S127.
  • MONTESSORI V, PRESS N, HARRIS M, AKAGI L, MONTANER JS: Adverse effects of antiretroviral therapy for HIV infection. CMAI (2004) 170:229–238.
  • AMMASSARI A, MURRI R, PEZZOTTI P et al: Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. I Acquir. Immune Defic. Syndr. (2001) 28:445–449.
  • MORGELLO S, MAHBOOB R, YAKOUSHINA T, KHAN S, HAGUE K: Autopsy findings in a human immunodeficiency virus-infected population over 2 decades: influences of gender, ethnicity, risk factors, and time. Arch. Pathol Lab. Med. (2002) 126:182–190.
  • FRIIS-MOLLER N, SABIN CA, WEBER R et al: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl. I Med. (2003) 349:1993–2003.
  • ••Milestone article assessing the cardiovascular risk of ART.
  • ROSENTHAL E, POIREE M, PRADIER C et al: Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS (2003) 17: 1803-1809.
  • SHAM HL, KEMPF DJ, MOLLA A et al: ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. (1998) 42:3218–3224.
  • ROBERTS NA, MARTIN JA, KINCHINGTON D et al: Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 248:358–361.
  • LAL R, HSU A, GRANNEMAN G et al.: Mulitple Dose Safety, Tolerability and Pharmacokinetics of ABT-378 in Combination with Ritonavir. 5th Conference of Retroviruses and opportunistic Infections. Chicago, IL, USA (1998).
  • ABBOTT LABORATORIES: Kaletra Package Insert. (2004):03-5341-R1O-Rev. February, 2004.
  • ERON JJ, FEINBERG J, KESSLER HAet al.: Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J. Infect. Dis. (2004) 189:265–272.
  • •The pros and cons of once-daily Kaletra.
  • GUILLEMI S, ALEXANDER C, BONNER S et al.: Lopinavir trough concentration remains consistent for adult patients regardless of age. 7th International Congress on Drug Therapy in HIV-Infection. Glasgow (2004).
  • STEK A, MIROCHNICK M, CAPPARELLI E et al: Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026.XV International AIDS Conference. Bangkok, Thailand (2004).
  • SAEZ-LLORENS X, VIOLARI A, DEETZ CO et al: Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. (2003) 22:216–224.
  • •The safety and efficacy of Kaletra in children.
  • GUSTAVSON L, LAM W, BERTZ R et al: Assessment of the Bioequivence and Food Effects for Liquid and Soft Elastic Capsule Co-Formulations of ABT-378/ritonavir (ABT-378/r) iin Healthy Subjects. 40th Interscience Conference on Antimicriobial Agents and Chemotherapy. Toronto, Ontario, Canada (2000).
  • BERTZ R, CHIU Y, NAYLOR C, LUFF K, BRUN S: Lack of effect of gastric acid reducing agents on lopinavir/ritonavir plasma concentrations in HIV-infected patients. 7th International Conference on Drug Therapy IP HIV-Infection. Glasgow, United Kingdom (2004).
  • BOFFITO M, LUCCHINI A, MAIELLO A et al.: Lopinavir/ritonavir absorption in a gastrectomized patient. AIDS (2003) 17:136–137.
  • KUMAR GN, RODRIGUES AD, BUKO AM, DENISSEN JF: Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. ./. Pharmacol Exp. Ther. (1996) 277:423–431.
  • KEMPF DJ, MARSH KC, KUMAR G et al.: Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. (1997) 41:654–660.
  • IZZEDINE H, LAUNAY-VACHER V, LEGRAND M, LIEBERHERR D, CAUMES E, DERAY G: ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis. AIDS (2001) 15:662–664.
  • ARRIBAS J, PULIDO F, PENG J et al.: Evaluation of Multiple-Dose Pharmacokinetics of Lopinavir/Ritonavir (LPV/r) in HIV and HCV Co-Infected Subjects with Mild or Moderate Hepatic Insufficiency. 9th European AIDS Conference. Warsaw (2003).
  • ABBOTT LABORATORIES: Kaletra - European Summary of Product Characteristics. (2002) 20 March 2001.
  • WALMSLEY S, BERNSTEIN B, KING M et al.: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl. J. Med. (2002) 346:2039–2046.
  • •The safety and efficacy of Kaletra In treatment-naive adult patients.
  • RUANE P, MENDONCA J, TIMERMAN A et al.: Kaletra versus Nelfinavir in Antiretroviral Naive Subjects: Week 60 Comparison in a Phase III, Blinded, Randomized Clinical Trial. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina (2001).
  • DA SILVA B, KING M, CERNOHOUS P, KELLY C, TRESSLER R, BRUN S: Risk Factors for Body Fat Composition Changes in Antiretroviral Naive Patients Treated with Lopinavir/ritonavir (LPV/r) or Nelfinavir (NFV). 5th International Workshop on Adverse Drug Reactions and Lipodystrophy ill HIV Paris, France (2003).
  • GULICK R, DA SILVA B, MCMILLAN F et al.: Lopinavir/ritonavir (LPV/r)-Based Therapy in Antiretroviral (ARV)-Naive, HIV-Infected Patients: 6-year Follow-Up of Study 720.7th International Congress on Drug Therapy IP HIV Infection. Glasgow, UK (2004).
  • MURPHY RL, BRUN S, HICKS C et al: ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS (2001) 15:Fl-F9.
  • POLLARD R, THOMPSON M, HICKS C et al: Phase III Comparison of Lopinavir/ritonavir versus Investigator-Selected Protease Inhibitors in Single PI-Experienced, NNRTI-Naive Patients: 48-Week Results of Study M98-888.7th International Congress on Drug Therapy ill HIV-Infection. Glasgow, United Kingdom (2004).
  • BENSON CA, DEEKS SG, BRUN SC et al: Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus Type 1-infected protease inhibitor-experienced patients. I Infect. Dis. (2002) 185:599–607.
  • HICKS C, BRUN S, KING M et al: Kaletra (Lopinavir/ritonavir) Therapy in Single Protease Inhibitor Experienced Patients: 144 week Follow Up. 8th European Conference on Clinical Aspects and Treatment of HIV Infection. Athens, Greece (2001).
  • DANNER S, BRUN S, RICHARDS B et al: Kaletra (Lopinavir/ritonavir) and Efavirenz: 72-Week Safety and Efficacy Evaluation in Multiple PI-Experienced Patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, Illinois, USA (2001).
  • HSU A, ISAACSON J, BRUN S et al: Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2003) 47:350–359.
  • KEMPF DJ, ISAACSON JD, KING MS et al: Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ ritonavir therapy. Antivir: Ther. (2002) 7:165–174.
  • BERNSTEIN B, MOSELEY J, KING Met al.: Safety of Kaletra: Results from Phase II and III Clinical Trials. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment Buenos Aires, Argentina (2001).
  • •Combined safety analysis of registrational Phase II and III studies of Kaletra.
  • BERTZ R, FOIT C, BURT D et al: Assessment of the effect of nevirapine on the pharmacokinetics of lopinavir/ ritonavir (Kaletra) after multiple dosing in HIV-infected adults. XIV International AIDS Conference. Barcelona, Spain (2002).
  • CERNOHOUS P, BERNSTEIN B, MOSELEY J, KING M, BAUER E, SUN E: Safety and Efficacy of Lopinavir/ ritonavir in Women in a Phase III Study of Antiretroviral-Naive Subjects. XIV International AIDS Conference. Barcelona, Spain (2002).
  • SAEZ-LLORENS X, RENZ C, DEETZ C et al: Kaletra (ABT-378/ritonavir) in HIV-infected Children at 60 Weeks. 8th Conference on Retro viruses and Opportunistic Infections. Chicago, Illinois, USA (2001).
  • MAUSS S, STECHEL J, WILLERS R, SCHMUTZ G, BERGER F, RICHTER WO: Differentiating hyperlipidaemia associated with antiretroviral therapy. AIDS (2003) 17:189–194.
  • LEE GA, SENEVIRATNE T, NOOR MA et al.: The metabolic effects of lopinavir/ ritonavir in HIV-negative men. AIDS (2004) 18:641–649.
  • •Short-term metabolic effects of Kaletra monotherapy in HIV-negative healthy volunteers.
  • RICHTER W BERGER F, MAUSS S: Lopinavir/ritonavir Does Not Alter Very-Low-Density Lipoprotein (VLDL) Composition in HIV-infected Patients. 7th International Congress on Drug Therapy IP HIV Infection. Glasgow, United Kingdom (2004).
  • NEGREDO E, MOLTO J, BURGER D et al.: Lopinavir/Ritonavir Plus Nevirapine as a Nucleoside-Sparing Approach in Antiretroviral-Experienced Patients (NEKA Study). I Acquir. Immune Defic. Syndr. (2005) 38:47–52.
  • GATHE J, PODZAMCZER D, JOHNSON M et al: Once-Daily versus Twice-Daily Lopinavir/ritonavir in Antiretroviral-Naive Patients: 48-Week Results. 1 1 th Conference on Retro viruses and Opportunistic Infections. San Francisco, CA, USA (2004).
  • MARTINEZ E, DOMINGO P, GALINDO MJ et al: Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin. Infect. Dis. (2004) 38:1017–1023.
  • •Metabolic changes under a Kaletra-containing HAART regimen in a 'real-life' cohort of naive and pretreated HAT-positive patients.
  • NOOR MA, PARKER RA, O'MARA E et al: The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS (2004) 18:2137–2144.
  • CARR A, COOPER DA: Adverse effectsof antiretroviral therapy. Lancet (2000) 356:1423–1430.
  • FELLAY J, BOUBAKER K, LEDERGERBER B et al.: Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 358:1322–1327.
  • SENSION M, SHEN Y, BUSH L et al.: Gastrointestinal Tolerability After PI/ NNRTI Substitution of Lopinavir/ritonavir. 43rd Interscience Conference on Antimicrobial Agents Chemotherapy. Chicago, IL, USA (2003).
  • DA SILVA B, KING M, CERNOHOUS P, BRUN S: Lopinavir/ritonavir (LPV/r) Safety, Tolerability and Efficacy in Hepatitis C and/or Hepatitis B-infected Patients: Review of Clinical Trials. XV International AIDS Conference. Bangkok, Thailand (2004).
  • SULKOWSKI MS, THOMAS DL, CHAISSON RE, MOORE RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA (2000) 283:74–80.
  • GONZALEZ DE REQUENA D, BLANCO F, GARCIA-BENAYAS T, JIMENEZ-NACHER I, GONZALEZ-LAHOZ J, SORIANO V: Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS (2003) 17:443–445.
  • SEMINARI E, DANISE A, HASSON H et al.: Relationship between lopinavir troughs and liver function tests. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom (2004).
  • DURAN S, SAVES M, SPIRE B et al.: Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS (2001) 15:2441–2444.
  • MARTINEZ E, MOCROFT A, GARCIA-VIEJO MA et al: Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet (2001) 357:592–598.
  • BERNASCONI E, BOUBAKER K, JUNGHANS C et al: Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J. Acquir: Immune Defic. Syndr. (2002) 31:50–55.
  • MALLON PW, MILLER J, COOPER DA, CARR A: Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS (2003) 17:971–979.
  • BRINKMAN K, SMEITINK JA, ROMIJN JA, REISS P: Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet (1999) 354:1112–1115.
  • BONFANTI P, GULISANO C, RICCI E et al.: Risk factors for lipodystrophy in the CISAI cohort. Biomed. Pharmacother. (2003) 57:422–427.
  • SAVES M, RAFFI F, CAPEAU J Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin. Infect. Dis. (2002) 34:1396–405.
  • BUCHER HC, YOUNG J, BATTEGAY M: Protease inhibitor-sparing simplified maintenance therapy: a need for perspective. J. Antimicrob. Chemother. (2004) 54:303–305.
  • QURISHI N, KREUZBERG C, LUCHTERS G et al: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet (2003) 362:1708–1713.
  • •The beneficial effect of HAART on liver-related mortality in HAT-positive patients.
  • LIM ML, MIN SS, ERON JJ et al: Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction Through Cytochrome P450 Induction. J. Acquir. Immune Defic. Syndr. (2004) 36:1034–1040.
  • DI CENZO R, PETERSON D, CRUTTENDEN K et al: Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. (2004) 48:4328–4331.
  • BERTZ R, FOIT C, CHIU Y et al: Mulitple-Dose Kaletra (Lopinavir/ritonavir) Does Not Affect the Pharmacokinetics of the CYP2D6 Probe, Desipramine. Seattle, WA, USA (2002).
  • BOFFITO M, BONORA S, SALES P et al: Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting. AIDS Res. Hum. Retroviruses (2003) 19:941–942.
  • BONORA S, BOFFITO M, D'AVOLIO A et al: Pharmacokinetics (PKS) of Rifabutin (RIF) Coadminstered with Lopinavir/ ritonavir (LPV/r) in HIV Patients Affected by Tuberculosis (TB). 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France (2002).
  • LA PORTE CJ, COLBERS EP, BERTZ R et al: Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob. Agents Chemother. (2004) 48:1553–1560.
  • CARR R, ANDREA, BERTZ R et al: Concomittant Administration of ABT-378/ ritonavir (ABT378/r) Results in a Clinically Important Pharmacokinetic (PK) Interaction with Atorvastatin (ATO) but not with Pravastatin (PRA). 40th Interscience Conference on Antimicrobial Agents ChemotherapyToronto, Canada (2000).
  • VOGEL M, VOIGT E, MICHAELIS HC et al: Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl. (2004) 10:939–944.
  • JAIN AB, VENKATARAMANAN R, EGHTESAD B et al: Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl. (2003) 9:954–960.
  • CLARKE S, MULCAHY F, BERGIN C et al: Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin. Infect. Dis. (2002) 34:1143–1145.
  • RAPAPORT S, MAROLODO-CONNELLY L,PATTERSON J, STEVENS R: Lack of methadone dose alterations or withdrawal symptoms with lopinavid ritonavir (Kaletra). XIV International AIDS Conference. Barcelona, Spain (2002).
  • SOLAS C, POIZOT-MARTIN I, DROGOUL MP et al: Therapeutic drug monitoring of lopinavidritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br. Pharmacol (2004) 57:436–440.
  • KEARNEY B, MITTAN A, SAYRE J: Pharmacokinetic interaction and long term safety profile of tenofovir DF and lopinavir/ ritonavir. 43rd Interscience Conference on Antimicrobial Agents Chemotherapy. Chicago, IL, USA (2003).
  • KRUSE G, STOCKER H, BRESKE A et al.: Trough levels of six different Atazanavir regimens in HIV-infected patients. 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy (2004).
  • CORBETT A, DAVIDSON L, PARK J et al: Dose Separation Strategies to Overcome the Pharmacokinetic Interaction of a Triple Protease Inhibitor Regimen Containing Fosamprenavir Lopinavir, and Ritonavir. 11th Conference on Retro viruses and Opportunistic Infections. San Francisco, USA (2004).
  • BERTZ R, FOIT C, ASHBRENNER E et al: Assessment of the Steady-State Pharmacokinetic Interaction of Lopinavir/ ritonavir with Either Indinavir or Saquinavir in Healthy Subjects. 42nd Intescience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002).
  • WALMSLEY S, LEITH J, KATLAMA C et al: Pharmacokinetics and Safety of Tipranavir/ritonavir Alone or in Combination with Saquinavir (SQV), Amprenavir (APV), or Lopinavir (LPV): Interim Analysis of BI 1182.51.XV International AIDS Conference. Bangkok, Thailand (2004).

Websites

  • http://aidsinfo.nih.gov. US Department of Human Health Services (DHHS): Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents (2004). Comprehensive guideline on ART In the treatment of HIV-infection.
  • www.hiv-druginteractions.org. Liverpool HIV pharmacology group: HIV Drug Interactions (2004).
  • ••Regularly updated website on drug—drugInteractions of antiretroviral drugs.
  • http://www.aidsinfo.nih.gov/guidelines/ perinatal/PER_121704.pdf. Perinatal HIV guidelines working group: Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.